Washington University and Sun Pharma Advanced Research Company are in their second year of their partnership, called SPARC LEAP to accelerate the development of potential new medicines for a wide range of diseases.

SPARC LEAP will support projects selected from across WUSTL’s broad research enterprise, with a focus on early stage translational therapeutic work in the areas of oncology, neurodegeneration, inflammation, dermatology, and ophthalmology.

Each selected project will have the potential to receive a value up to $1.5 million over a three-year period, including in-kind support in areas such as medicinal chemistry and preclinical development.

The SPARC-LEAP partnership will offer two funding competitions per year for WUSTL faculty. Registration for SPARC occurs in Jan and August.

The current registration period opens Jan 27 and closes Feb 17 at 5pm.

REGISTER HERE

SPARC (CIN: L73100GJ2006PLC047837) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC consistently aims to lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life.